Here are five things to know:
1. The study will involve 160 participants.
2. The VA plans to start the study in October 2016.
3. Six VA medical centers with spinal cord injury services in California, Florida, Massachusetts, Texas and Virginia will participate.
4. The ReWalk exoskeleton is the only FDA-cleared technology for spinal cord injury patients.
5. This study will be the first to assess an exoskeleton’s impact on daily life.
More articles on devices:
K2M Group Holdings shares hit 52-week low: 5 notes
Medovex obtains reimbursement for its DenerveX Facet Joint Syndrome Treatment: 4 takeaways
Global non-fusion spinal device market to grow – 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.